Evidence map›Paper›PMID 39793060›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Binding mode-guided development of high-performance antibodies targeting site-specific posttranslational modifications.

Mariapia Riso, Rohan N Shah, Akiko Koide, Alexander J Ruthenburg, Shohei Koide, Takamitsu Hattori

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariapia RisoLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Rohan N ShahPritzker School of Medicine, The University of Chicago, Chicago, IL 60637.
Akiko KoideLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Alexander J RuthenburgDepartment of Molecular Genetics and Cell Biology, The University of Chicago, Chicago, IL 60637.ORCID 0000-0003-2709-4564
Shohei KoideLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0001-5473-4358
Takamitsu HattoriLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0002-5502-2595

Funding

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)T32HD007009 · NICHD · UNIVERSITY OF CHICAGO · PI NANCY B SCHWARTZ · 1985 to 2026
$13.0M
Defining the mechanisms of epigenetic information flowR35GM145373 · NIGMS · UNIVERSITY OF CHICAGO · PI Alexander Jackson Ruthenburg · 2022 to 2026
$2.1M
Quantitatively probing intra-nucleosomal chromatin variation and functionR01GM115945 · NIGMS · UNIVERSITY OF CHICAGO · PI RUTHENBURG, ALEXANDER JACKSON · 2016 to 2020
$1.6M
Rational generation of high-performance recombinant antibodies to post-translational modificationsR21CA246457 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HATTORI, TAKAMITSU · 2020 to 2020
$620k
HHS | NIH (NIH) R01GM115945HHS | NIH (NIH) R21CA246457HHS | NIH (NIH) R35GM145373HHS | NIH (NIH) T32HD007009-45NCI NIH HHS R21 CA246457NICHD NIH HHS T32 HD007009NIGMS NIH HHS R01 GM115945NIGMS NIH HHS R35 GM145373
6 · The paper itself

Abstract

Posttranslational modifications (PTMs) of proteins play critical roles in regulating many cellular events. Antibodies targeting site-specific PTMs are essential tools for detecting and enriching PTMs at sites of interest. However, fundamental difficulties in molecular recognition of both PTM and surrounding peptide sequence have hindered the efficient generation of highly sequence-specific anti-PTM antibodies. Furthermore, the widespread use of potentially inconsistent, nonrenewable, and molecularly undefined antibodies presents experimental challenges thought to contribute to the reproducibility problem in biomedical research. In this study, we describe the binding mode-guided development of a platform that efficiently generates potent and selective recombinant antibodies to PTMs that are molecularly defined and renewable. Our platform is built on our previous discovery of an unconventional binding mode of anti-PTM antibodies, antigen clasping, where two antigen binding sites cooperatively sandwich a single antigen, creating extensive interactions with the antigen and leading to high selectivity and potency. We designed the platform that generates clasping antibodies with two distinct binding units, resulting in efficient generation of antibodies to a set of trimethylated histone H3 with high levels of specificity and affinity. Performance comparison in chromatin immunoprecipitation, a common application in epigenomics, revealed that a clasping antibody to trimethylated histone H3 at lysine 27 exhibited superior specificity to a widely used conventional antibody and captured symmetric and asymmetric nucleosomes in a less biased manner. We further generated clasping antibodies to phosphotyrosine antigens by using the same principle. These results suggest the broad applicability of our platform to generating high-performance clasping antibodies to diverse PTMs.

Indexed as

HistonesProtein Processing, Post-TranslationalAnimalsAntibodiesBinding SitesHumansProtein BindingAntibodiesHistonesaffinity reagentsepigeneticshistone modificationsprotein engineeringsignaling

Identifiers

PMID39793060
PMCPMC11725865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.